While progression-free and overall survival figures were similar in the cohort of patients receiving G-CSF and those in the control arm (Table 1), a difference was noted in the percentage of patients free from lymphoma progression at 10 years (68% G-CSF intervention arm vs 47% control arm). This evidence concerns the gene CSF3 and lymphoma.